P
Peter S. Nelson
Researcher at Fred Hutchinson Cancer Research Center
Publications - 497
Citations - 57568
Peter S. Nelson is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 96, co-authored 425 publications receiving 47923 citations. Previous affiliations of Peter S. Nelson include University of Washington & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.
Mary-Ellen Taplin,Robert B. Montgomery,Christopher J. Logothetis,Glenn J. Bubley,Jerome P. Richie,Bruce L. Dalkin,Martin G. Sanda,Massimo Loda,Lawrence D. True,Patricia Troncoso,Elizabeth M. Genega,Steven P. Balk,Peter S. Nelson,Wanling Xie,Christopher M. Haqq,Namphuong Tran,Cameron S. Liu,Thian Kheoh,Arturo Molina,Philip W. Kantoff +19 more
TL;DR: Results confirmed that LHRPC is infrequently cured with prostatectomy and neoadjuvant androgen deprivation therapy (ADT) has not improved outcomes and residual intra-prostatic androgens remain.
Journal ArticleDOI
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
Kendal Jensen,Eric Q. Konnick,Michael T. Schweizer,Michael T. Schweizer,Alexandra O. Sokolova,Petros Grivas,Petros Grivas,Heather H. Cheng,Heather H. Cheng,Nola Klemfuss,Mallory Beightol,Evan Y. Yu,Peter S. Nelson,Peter S. Nelson,Bruce Montgomery,Bruce Montgomery,Colin C. Pritchard +16 more
TL;DR: Men with prostate cancer are at high risk of being misdiagnosed as being eligible for PARPi therapy using current cfDNA tests; assays should use a whole-blood control sample to distinguish CHIP variants from prostate cancer.
Journal ArticleDOI
Prostate tissue androgens: history and current clinical relevance.
TL;DR: Direct determination of androgen levels in prostate tissue provides a perspective on the organ that is not available via androgen serum levels, and determination of prostate tissue androgens may soon transition from research tool to clinical test.
Journal ArticleDOI
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.
Michael T. Schweizer,Michael T. Schweizer,Emmanuel S. Antonarakis,Tarek A. Bismar,Liana B. Guedes,Heather H. Cheng,Heather H. Cheng,Maria S. Tretiakova,Funda Vakar-Lopez,Nola Klemfuss,Eric Q. Konnick,Elahe A. Mostaghel,Elahe A. Mostaghel,Andrew C. Hsieh,Peter S. Nelson,Evan Y. Yu,Evan Y. Yu,R. Bruce Montgomery,Lawrence D. True,Jonathan I. Epstein,Tamara L. Lotan,Colin C. Pritchard +21 more
TL;DR: This study strongly suggests that dPCs are enriched for actionable mutations, with approximately 50% of patients demonstrating DNA damage repair pathway alteration(s), and patients with dPC should be offered next-generation sequencing to guide standard-of-care treatment or triaged toward an appropriate clinical trial.
Journal ArticleDOI
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
Stephen R. Plymate,Kathy Haugk,Ilsa Coleman,Lillie Woodke,Robert L. Vessella,Peter S. Nelson,R. Bruce Montgomery,Dale L. Ludwig,Jennifer D. Wu +8 more
TL;DR: This study shows that the inhibition of IGF-IR enhances the effects of castration in prostate cancer, which are associated with a decrease in AR signaling and nuclear AR localization, and recurrence is associated with an increase in AR-regulated gene expression.